New Trial Suggests CV Benefit With EPA: RESPECT-EPA : vimars

Although the open-label trial has many limitations, it could add some support to findings from the REDUCE-IT study, which showed a reduction in cardiovascular events with high-dose eicosapentaenoic acid.

Related Keywords

Japan , United States , Japanese , American , Deepak Bhatt , Pamr Taub , Steve Nissen , Hiroyuki Daida , American Heart Association , Juntendo University Graduate School Of Medicine , Japan Heart Foundation , Scientific Sessions , Juntendo University Graduate School , Medscape Cardiology , Intervention Study , Cleveland Clinic , Secondary Prevention Efficacy , Combination Therapy Statin , Late Breaking Clinical Trials , California San Diego School , Japan Heart , Cv , Ardiovascular , Lipids , Ipid Management , Atherosclerotic Heart Disease , Therosclerotic Cardiovascular Disease , Oronary Heart Disease , Schemic Heart Disease , Angina , Angina Pectoris , Statin , Lipid Lowering Drugs , Rug Lipid Lowering , Acute Coronary Syndrome Acs , Cute Coronary Syndrome , Cs , Atrial Fibrillation , F Atrial Fibrillation , Thromboembolism , Stroke , Erebrovascular Accident , Gva C ,